| Name | Phenoxodiol |
| Description | Phenoxodiol (Idronoxil) activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis(XIAP), disrupts FLICE inhibitory protein(FLIP) expression, and sensitizes the cancer cells to Fas-mediated apoptosis. Phenoxodiol induces cell cycle arrest in the G1/S phase of the cell cycle and upregulates p21WAF1 via a p53 independent manner. Phenoxodiol also inhibits DNA topoisomerase II. |
| In vitro | Phenoxodiol, at concentrations >or=1 microg/ml (4 microM), inhibited proliferation and reduced the viability of healthy donor-derived PBMC. In contrast, lower Phenoxodiol concentrations (0.05-0.5 microg/ml) augmented, upon 3-day incubation, peripheral blood mononuclear cells cytotoxicity. Experiments with purified CD56(+) lymphocytes revealed that Phenoxodiol enhanced the lytic function of natural killer cells by directly stimulating this lymphocytic subpopulation[3]. |
| In vivo | Balb/C mice administered low-dose Phenoxodiol exhibited significantly reduced tumour growth rates and prolonged survival (in 40% of the animals) in a colon cancer model[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (208.12 mM)
|
| Keywords | inhibit | Inhibitor | Topoisomerase | Caspase | XIAP | CP70 | Apoptosis | ovarian cancer | prostate cancer | Phenoxodiol |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Protease Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
